- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT04062773
Time-Restricted Feeding on Glucose Homeostasis and Quality of Life
A Pilot Study to Evaluate the Effect of Time-Restricted Feeding on Blood Glucose, Insulin Sensitivity and Quality of Life
Background: Time-restricted feeding can improve insulin sensitivity, and increase fat oxidation in people with prediabetes independent of weight loss. It may also help people to lose weight. However, it has not been tested in people with type 2 diabetes.
Plan of investigation: Participants meeting the eligibility criteria will be randomized to the TRF arm or the continuous eating arm. Both arms with be given a prescribed dietary plan to help them lose 5% of body weight. In the TRF they will permitted to eat between midday and 6pm. In the continuous eating arm they will be allowed to eat between 8am and 11pm. Participants will attend the nutrition clinic every two weeks to be weighed and be given personalized support to help them follow their assigned diet. Prior to starting the diets outcome measures will be taken: Glycaemia will be measured by a glucose tolerance test, and 7-day continuous glucose monitoring. HbA1c will be taken from fasting blood sample. In addition, the fasting sample will be taken for measurement of insulin, lipid profile and inflammatory markers. We will also use questionnaires to assess quality of life, a 3-day food diary to assess compliance to diet especially meal timings. Capillary ketones will also be used to assess whether compliance to the assigned fasting period. Outcome measures will also be taken during 7 days of the second month, and then the final seven days of the last month on the diet. The primary outcome is HbA1c.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
Experimental Design
12-week parallel randomised control trial
Recruitment
We will recruit via advertisements outside Dasman using social media and local ads in addition to screening of Dasman Registry for any potential participants. Opportunistic recruitment will also occur by DDI dietitians. Following telephone screening to ensure the potential participant meets initial screening criteria we will carry out a medical screening to ensure the person can take part.
Environment All screening, dietary counselling visits, and placement of the CGM will take place at the Dasman Diabetes Institute (DDI). The institute has extensive space for interventional studies, including screening rooms, body composition assessment and clinical rooms for placement of the CGM monitor.
STUDY INTERVENTIONS
For both groups all participants will be guided towards a 5% weight loss based on individualised energy requirements. The difference will be the hours during which the participants consume their required calories.
- Time restricted feeding group: Will consume their calories between 12pm and 6pm.
- Continuous energy restriction group: Will consume their calories between 8am and 11pm.
Participants will be guided towards their weight loss during one-to-one visits at baseline and every 2 weeks for 12 weeks.
Procedures
- At baseline and follow-up all participants will undergo an oral glucose tolerance test.
- A blood sample will also be taken for HbA1c, lipid profile, fasting insulin, inflammatory factors and a sample for Biobank. The biobank sample will be stored to enable us, with other researchers at DDI to understand the heterogeneity of type 2 diabetes; whether certain people respond to dietary interventions based on their genetic, epigenetic or metabolomic background; and ultimately will help guide clinical care.
- Participants will wear Flash Glucose monitoring or other continuous glucose monitoring device to measure their 24-hour blood glucose concentrations during the seven days preceding the start of the dietary intervention, seven days of the second month, and the final seven days of the third month.
- Participants will also measure their capillary ketones during the first three days of the first month, three days of the second month, and final three days of the third month.
- Medication changes: prandial medications (insulin or sulphonylurea) will be altered to the timing of meal intake. Any reduction in medication due to changes in glucose will be carried out by the patient's doctor.
- A quality of life questionnaire: PAID.
- A 3 day food diary with meal times to check compliance.
Statistical Methods
This is a pilot study. We will recruit 25 people per group. This is based on recommendations for sample sizes for feasibility and pilot studies.
Opintotyyppi
Ilmoittautuminen (Odotettu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Nicola Guess, PhD
- Puhelinnumero: 2033 +965 2224 2999
- Sähköposti: Nicola.Guess@dasmaninstitute.org
Opiskelupaikat
-
-
-
Kuwait City, Kuwait, 15462
- Rekrytointi
- Dasman Diabetes Institute
-
Ottaa yhteyttä:
- Nicola Guess, PhD
- Puhelinnumero: 2033 +965 2224 2999
- Sähköposti: Nicola.Guess@dasmaninstitute.org
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Must agree to follow time restricted feeding protocol if randomized to the TRF arm.
- Age 21-65 years
- T2DM with any diabetes medication
- BMI of 25-45 kg/m2
- Wake up at a regular time between 5-8 am
- Able to provide informed consent.
Exclusion Criteria:
- Weight loss of more than 5 kg within the past 6 months
- HbA1c of <6·5% and >12%
- Serious current or recent illness including cancer or severe or unstable heart failure.
- Participation in another clinical research trial.
- Current treatment with anti-obesity drugs.
- Substance abuse
- Learning difficulties
- Presence of an eating disorder
- Purging behaviour
- Pregnancy or consideration of pregnancy
- Hospital admission for depression or use of antipsychotic drugs.
- Regularly eat within a <9-hour period each day
- Inability or unwillingness of individual or legal guardian/representative to give written informed consent.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: TRF
Eating restricted to between midday and 6pm.
|
time restricted feeding group
|
Placebo Comparator: Normal timing of food intake.
Eating between 8am and 11pm.
|
no time restricted feeding
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
HbA1c
Aikaikkuna: 12 weeks
|
Change in HbA1c between the intervention and control arms.
|
12 weeks
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Body weight
Aikaikkuna: 12 weeks
|
Change in body weight between the intervention and control arms.
|
12 weeks
|
Insulin sensitivity
Aikaikkuna: 12 weeks
|
Change insulin sensitivitiy assessed by OGTT between the intervention and control arms.
|
12 weeks
|
Diabetes medications
Aikaikkuna: 12 weeks
|
Change in diabetes medications between the intervention and control arms.
|
12 weeks
|
Inflammatory markers
Aikaikkuna: 12 weeks
|
Change in TNF-alpha in pg/mL between the intervention and control arms.
|
12 weeks
|
Inflammatory markers
Aikaikkuna: 12 weeks
|
Change in IL-10 in pg/mL between the intervention and control arms.
|
12 weeks
|
Inflammatory markers
Aikaikkuna: 12 weeks
|
Change in IL-6 in pg/mL between the intervention and control arms.
|
12 weeks
|
Inflammatory markers
Aikaikkuna: 12 weeks
|
Change in IL-18 in pg/mL between the intervention and control arms.
|
12 weeks
|
Inflammatory markers
Aikaikkuna: 12 weeks
|
Change in CRP in mg/L between the intervention and control arms.
|
12 weeks
|
Inflammatory markers
Aikaikkuna: 12 weeks
|
Change in adiponectin in µg/mL the intervention and control arms.
|
12 weeks
|
Yhteistyökumppanit ja tutkijat
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Odotettu)
Opintojen valmistuminen (Odotettu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- RA HM-2019-012
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset Diabetes mellitus, tyyppi 2
-
Griffin HospitalCalifornia Walnut CommissionValmisTYYPIN DIABETES MELLITUS 2Yhdysvallat
-
Diabetes Free, Inc.Ei vielä rekrytointiaDiabetes mellitus tyyppi 2 - Insuliinilla hoidettu
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Ei vielä rekrytointiaTyypin 2 diabetes mellitus
-
Endogenex, Inc.Ei vielä rekrytointiaDiabetes mellitus, tyyppi 2 | Diabetes | Tyypin 2 diabetes mellitus | Tyypin 2 diabetes | Tyypin 2 diabetes
-
Nanjing First Hospital, Nanjing Medical UniversityRekrytointiTyypin 2 diabetes mellitusKiina
-
Xiangya Hospital of Central South UniversityRekrytointi
-
University of Alabama at BirminghamValmisTyypin 2 diabetes mellitusYhdysvallat
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...ValmisTyypin 2 diabetes mellitusYhdistynyt kuningaskunta
-
Universiti Sains MalaysiaValmis
-
University of Alabama at BirminghamUnited States Department of Defense; Loma Linda University; Brenda Davis Nutrition... ja muut yhteistyökumppanitValmisTyypin 2 diabetes mellitus
Kliiniset tutkimukset TRF
-
University of AdelaideSalk Institute for Biological Studies; University of South AustraliaValmisLihavuus | Tyypin 2 diabetesAustralia
-
University of AdelaideSalk Institute for Biological StudiesLopetettuInsuliiniresistenssi | Tyypin 2 diabetesAustralia
-
Federal University of Minas GeraisRekrytointi
-
Guangdong Provincial Hospital of Traditional Chinese...ValmisLihavuus | Munuaisten vajaatoiminta, krooninen | Aikarajoitettu ruokintaKiina
-
University of Alabama at BirminghamRekrytointi
-
German Institute of Human NutritionCharite University, Berlin, Germany; University of Potsdam; Immanuel Krankenhaus... ja muut yhteistyökumppanitRekrytointiAikarajoitettu ruokinta ruokavaliostrategiana ihmisten aineenvaihduntahäiriöitä vastaan (ChronoFast)Ylipaino ja lihavuusSaksa
-
Julie PendergastNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RekrytointiMetabolinen oireyhtymä | Postmenopausaaliset oireetYhdysvallat
-
Fundació Sant Joan de DéuRekrytointiLihavuus, Lapsuus | Liikalihavuus, nuoriEspanja
-
University of Illinois at ChicagoAktiivinen, ei rekrytointiLihavuus | Diabetes mellitus, tyyppi 2Yhdysvallat